2005
DOI: 10.1007/s00280-005-1009-0
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Paclitaxel and gemcitabine can be safely administered at a high dose intensity on an every-other-week schedule. The recommended phase II dose is paclitaxel 175 mg/m2 and gemcitabine 2,500 mg/m2.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
3
0

Year Published

2005
2005
2008
2008

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 5 publications
(3 citation statements)
references
References 15 publications
0
3
0
Order By: Relevance
“…1,2 Concurrent treatment with corticosteroids may not prevent the development of drug-induced pneumonitis. [3][4][5][6][7] Elevated WBC count in peripheral blood, elevated erythrocyte sedimentation rate, and elevated C-reactive protein levels are also common nonspecific laboratory findings. Chest imaging may show diffuse or patchy, unilateral or bilateral, ground-glass opacities or consolidations.…”
Section: Clinical Manifestations and Diagnosismentioning
confidence: 99%
“…1,2 Concurrent treatment with corticosteroids may not prevent the development of drug-induced pneumonitis. [3][4][5][6][7] Elevated WBC count in peripheral blood, elevated erythrocyte sedimentation rate, and elevated C-reactive protein levels are also common nonspecific laboratory findings. Chest imaging may show diffuse or patchy, unilateral or bilateral, ground-glass opacities or consolidations.…”
Section: Clinical Manifestations and Diagnosismentioning
confidence: 99%
“…Growth factor (granulocytecolony stimulating factor [G-CSF]) support is not usually used in paclitaxel combinations. These drugs have also been evaluated in Phase I studies using a biweekly schedule [19,20]. As a single drug, a Phase I study showed that biweekly gemcitabine could be delivered in doses up to 5700 mg/m 2 [21].…”
mentioning
confidence: 99%
“…When paclitaxel and gemcitabine were combined biweekly, dose-limiting toxicities were febrile neutropenia and, in one study, alanine transaminase (ALT) elevations. Doses recommended for biweekly Phase II studies are paclitaxel 150 mg/m 2 plus gemcitabine 3000 mg/m 2 [19] or 2500 mg/m 2 [20].…”
mentioning
confidence: 99%